Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Calquence in Very Old or Frail CLL Patients
NCT04883749Phase 2Completed
- Sponsor
- German CLL Study Group
- Start
- Jun 2021
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of acalabrutinib in chronic lymphocytic leukemia (CLL), sponsored by German CLL Study Group. Started Jun 2021; status: completed.
02
Drugs
acalabrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT04883749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04883749.